A Novel Nanoformulation of α-Eleostearic Acid Restores Molecular Pathogenesis of Hypersensitivity

What is it about?

The present study provided empirical evidences and importance of formulating bio-active lipids as nano-emulsions over conventional emulsions for therapeutic purpose against chronic clinical conditions of hypersensitivity. Due focus on molecular marker expression studies and therapeutic targets have been covered in the present study to highlight the importance of nano-sizing bio-active therapeutic lipids. Further, the present study reports of a novel formulation comprising GRAS excipients that can easily be commercialized for scaled-up applications. In silico data have also been appended with the wet model findings to corroborate the importance of alpha-eleostearic acid (a conjugated linolenic acid isomer), the major bio-active constituent present in bitter melon seed oil in treating hypersensitivity manifestations. The study proposes a potent novel nutraceutical formulation that can be ushered in for clinical applications against immunological disorders arising from hypersensitivity.

Featured Image